Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
NCT ID: NCT01272128
Last Updated: 2015-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2012-12-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
NCT02076841
Avonex 15 Year Long Term Follow-up Study
NCT00525343
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
NCT00599274
Immunogenicity and Safety Study of Serum-Free Avonex
NCT00912860
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
NCT00037102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon beta-1a
Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Study enrollment must occur prior to 4th weekly administration of IFN beta-1a
* Able to understand and complete a self-administered questionnaire
* No contra-indications for IFN beta-1a
Exclusion Criteria
* Subjects with primary or secondary progressive MS
* Subjects with current severe depression and/or suicidal ideation
* Pregnant women
* Subjects participating in another clinical trial
* Subjects who do not want to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Bonheiden, Antwerp, Belgium
Research Site
Middelheim, Antwerp, Belgium
Research Site
Ottignies, Brabant Wallon, Belgium
Research Site
Woluwe, Brussels Capital, Belgium
Research Site
Aalst, East Flanders, Belgium
Research Site
Saint Niklaas, East Flanders, Belgium
Research Site
Tielt, East Flanders, Belgium
Research Site
Baudour, Hainaut, Belgium
Research Site
Charleroi, Hainaut, Belgium
Research Site
Charleroi, Hainaut, Belgium
Research Site
La Louvière, Hainaut, Belgium
Research Site
Tournai, Hainaut, Belgium
Research Site
Hasselt, Limburg, Belgium
Research Site
Liège, Liège, Belgium
Research Site
Verviers, Liège, Belgium
Research Site
Libramont, Luxembourg, Belgium
Research Site
Sijsele, West Flanders, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BE-AVO-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.